Intersect ENT Inc. (NASDAQ:XENT)’s share price was up 3.1% on Tuesday . The company traded as high as $15.70 and last traded at $15.53, with a volume of 185,525 shares traded. The stock had previously closed at $15.06.

A number of equities analysts have recently weighed in on XENT shares. Zacks Investment Research lowered Intersect ENT from a “hold” rating to a “sell” rating in a research report on Wednesday, April 27th. BTIG Research assumed coverage on Intersect ENT in a report on Tuesday, July 12th. They set a “neutral” rating for the company. Wedbush reiterated an “outperform” rating and set a $25.00 price target on shares of Intersect ENT in a report on Monday, July 18th. Finally, Canaccord Genuity reiterated a “buy” rating on shares of Intersect ENT in a report on Monday, July 18th. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $24.20.

The firm’s market capitalization is $438.76 million. The stock’s 50-day moving average price is $14.78 and its 200 day moving average price is $15.98.

Intersect ENT (NASDAQ:XENT) last issued its quarterly earnings data on Tuesday, August 2nd. The company reported ($0.21) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.26) by $0.05. The business earned $19.30 million during the quarter, compared to the consensus estimate of $18.91 million. During the same quarter in the prior year, the business posted ($0.23) earnings per share. Intersect ENT’s quarterly revenue was up 27.0% compared to the same quarter last year. Analysts expect that Intersect ENT Inc. will post ($0.96) earnings per share for the current fiscal year.

In other news, VP James Stambaugh sold 3,977 shares of Intersect ENT stock in a transaction that occurred on Wednesday, August 3rd. The stock was sold at an average price of $17.00, for a total value of $67,609.00. Following the sale, the vice president now directly owns 27,977 shares in the company, valued at approximately $475,609. The sale was disclosed in a filing with the SEC, which is available through this link.

An institutional investor recently raised its position in Intersect ENT stock. RS Investment Management Co. LLC boosted its position in shares of Intersect ENT Inc. (NASDAQ:XENT) by 68.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,328,250 shares of the company’s stock after buying an additional 538,720 shares during the period. RS Investment Management Co. LLC owned 4.74% of Intersect ENT worth $29,886,000 at the end of the most recent quarter.

Intersect ENT, Inc is a commercial stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. It has developed a drug releasing bio-absorbable implant technology that enables targeted and sustained release of therapeutic agents. Its commercial products are the PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.